Products
Pre-made Obinutuzumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-385
Pre-Made Obinutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-385-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Obinutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| INN Name | Obinutuzumab |
| Target | CD20 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 3pp3:HL:IK/3pp4:HL |
| 99% SI Structure | 6y9a:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2011 |
| Companies | GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds |
| Conditions Approved | Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma |
| Conditions Active | Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia |
| Conditions Discontinued | Primary biliary cirrhosis |
| Development Tech | GlycoMAb Technology |
<